Amyotrophic Lateral Sclerosis 2021
DOI: 10.36255/exonpublications.amyotrophiclateralsclerosis.microbiota.2021
|View full text |Cite
|
Sign up to set email alerts
|

Gastrointestinal Status and Microbiota Shaping in Amyotrophic Lateral Sclerosis: A New Frontier for Targeting?

Abstract: Amyotrophic lateral sclerosis (ALS) is a rare and severe neurodegenerative disease affecting the upper and lower motor neurons, causing diffuse muscle paralysis. Etiology and pathogenesis remain largely unclear, but several environmental, genetic, and molecular factors are thought to be involved in the disease process. Emerging data identify a relationship between gut microbiota dysbiosis and neurodegenerative diseases, such as Parkinson' s disease, Alzheimer' s disease, and ALS. In these disorders, neuroinfla… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
2
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 92 publications
(104 reference statements)
0
2
0
Order By: Relevance
“…Citramalate, a metabolite once known as being exclusively present in yeast or anaerobic bacteria, is commonly used to diagnose gut dysbiosis in humans [ 55 ]. Alterations in gut microbiota can impact the gut-to-brain axis and have been associated with the occurrence of neurodegenerative diseases, including ALS [ 56 , 57 , 58 ]. Different microbiomes in ALS mouse models and patients were reported, with consequent differences in microbiome-related metabolites [ 59 , 60 , 61 ].…”
Section: Discussionmentioning
confidence: 99%
“…Citramalate, a metabolite once known as being exclusively present in yeast or anaerobic bacteria, is commonly used to diagnose gut dysbiosis in humans [ 55 ]. Alterations in gut microbiota can impact the gut-to-brain axis and have been associated with the occurrence of neurodegenerative diseases, including ALS [ 56 , 57 , 58 ]. Different microbiomes in ALS mouse models and patients were reported, with consequent differences in microbiome-related metabolites [ 59 , 60 , 61 ].…”
Section: Discussionmentioning
confidence: 99%
“…In our study, we analyzed a broad spectrum of blood-based biological markers to delve into the increasingly recognized role of microbiome, metabolism, and immunity in ALS pathogenesis [ 47 ]. Our comprehensive assessment included 14 inflammatory cytokines, 18 free fatty acids (end products of human and microbial metabolism), and TTV viremia, a virome-related potential marker linked to immune system function [ 40 ].…”
Section: Discussionmentioning
confidence: 99%
“…These factors are not only involved in the multistep process of ALS development, but also influence the pace of disease progression [ 48 ]. Their accessibility presents them as potential targets for research into diagnostic and prognostic biomarkers [ 47 ]. The underlying causes behind metabolic dysfunction, immune regulation failure, and sustained neuroinflammation in ALS remain mostly unknown.…”
Section: Introductionmentioning
confidence: 99%
“…One of the most discussed issues recently has been dysbiosis. Dysbiosis is defined as an imbalance in microbiota properties or functions because of decreased microbial diversity, increased pathogenic strains, and loss of beneficial strains [ 13 15 ]. It is hypothesized that the increased intestinal permeability in ALS in the interaction between microbiota and central nervous system facilitates the passage of toxins from the intestinal lumen into the blood, leading to an increase in circulating lipopolysaccharides and an immune response [ 16 ].…”
Section: Discussionmentioning
confidence: 99%